Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Posted on 04 Nov 2025
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment without knowing whether it will work. Now, researchers have developed a predictive blood-based model that offers a powerful new way to determine the likelihood of treatment success.
The Liquid Biomarker of Immunotherapy Outcomes (LiBIO) score, developed by researchers at the Cancer Center at Illinois (Urbana, IL, USA), in collaboration with MD Anderson Cancer Center (Houston, TX, USA), uses a liquid biopsy—analyzing blood samples—to noninvasively monitor immune changes during immunotherapy. Their research focused on predicting patient response to immune checkpoint blockade (ICB) therapy, a widely used but inconsistently effective immunotherapy approach.
Using a mouse model of head and neck squamous cell carcinoma (HNSCC), the researchers performed serial blood analyses before and after ICB treatment to track immune system dynamics. They found that early increases in specific immune cells—particularly effector memory T cells and B cells—were closely linked to favorable treatment outcomes. This observation allowed them to identify a gene signature representing these immune populations, which now forms the basis of the LiBIO score.
The team discovered that this early post-treatment time point is critical for predicting therapeutic response. By quantifying changes in these immune cell populations, the LiBIO score successfully distinguished responders from non-responders with far greater accuracy than previous biomarkers. Remarkably, the model also proved effective across multiple cancer types, including breast, lung, and melanoma, underscoring its broad clinical potential.
Because the LiBIO score is derived from blood samples, it offers a noninvasive and easily repeatable way to monitor patient progress at the molecular level. This enables clinicians to adjust treatment strategies in real time—maximizing benefits for patients who respond while avoiding unnecessary side effects and costs for those who do not. The researchers are now working to bring the technology into human clinical trials.
“This biomarker can help identify patients who are more likely to benefit from immunotherapy, thereby improving treatment efficacy and reducing the burden of unnecessary treatment,” said Cancer Center at Illinois member Kun Wang. “Because it is blood-based, it also offers a non-invasive way to monitor treatment progress at the molecular level, which is especially valuable for real-time clinical decision-making.”
Related Links:
Cancer Center at Illinois
MD Anderson Cancer Center
